Altimmune (ALT) Net Equity Issued and Repurchased (2011 - 2026)

Altimmune (ALT) has 13 years of Net Equity Issued and Repurchased data on file, last reported at $34.2 million in Q1 2026.

• On a quarterly basis, Net Equity Issued and Repurchased fell 1.58% year-over-year to $34.2 million in Q1 2026; TTM through Mar 2026 was $173.2 million, a 60.36% increase from a year earlier, with the FY2025 full-year figure at $173.7 million, up 1638.37% from the prior year.
• Net Equity Issued and Repurchased for Q1 2026 stood at $34.2 million, down from $61.6 million in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for ALT reached as high as $72.7 million in Q4 2023 and fell as low as $510000.0 in Q3 2023.
• Historically, Net Equity Issued and Repurchased has averaged $33.7 million across 4 years, with a median of $34.5 million in 2025.
• Across the five-year window, Net Equity Issued and Repurchased gained 17.43% in 2022 and slumped 98.4% in 2023, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $31.8 million in 2022, then soared by 128.53% to $72.7 million in 2023, then decreased by 15.25% to $61.6 million in 2025, then tumbled by 44.52% to $34.2 million in 2026.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $34.2 million in Q1 2026, $61.6 million in Q4 2025, and $39.5 million in Q3 2025.